Overview

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Albuterol
Glycopyrrolate
Lactitol
Tiotropium Bromide